Day One Biopharmaceuticals, Inc.
Day One Biopharmaceuticals, Inc. (DAWN) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · DAWN · as of Sep 30, 2025
Ownership Breakdown
176
Institutional Holders
▼ 4 vs Q2
$603.97M
Total Inst. Value
▲ $42.79M vs Q2
103.33M
Shares Outstanding
freeFloat 69.05%
85.68M
13F Shares Held
▼ 658,208 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
DAWN largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
FMR LLC pharmaceutical preparations | 10.10M | 9.80% | 9.80% | $71.19B | Nov 13, 2025 | ▼ 1.25M |
BLACKROCK, INC. pharmaceutical preparations | 9.00M | 8.73% | 8.73% | $63.46B | Nov 12, 2025 | ▼ 829.0K |
ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC pharmaceutical preparations | 6.43M | 6.24% | 6.24% | $45.33B | Nov 13, 2025 | — held |
VANGUARD GROUP INC pharmaceutical preparations | 6.18M | 6.00% | 6.00% | $43.58B | Nov 7, 2025 | ▲ 4.8K |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) pharmaceutical preparations | 4.71M | 4.57% | 4.57% | $33.17B | Nov 14, 2025 | ▲ 982.3K |
FRANKLIN RESOURCES INC pharmaceutical preparations | 3.48M | 3.37% | 3.37% | $24.51B | Nov 13, 2025 | ▼ 620.6K |
RUBRIC CAPITAL MANAGEMENT LP pharmaceutical preparations | 3.38M | 3.28% | 3.28% | $23.81B | Nov 14, 2025 | NEW |
STATE STREET CORP pharmaceutical preparations | 3.24M | 3.14% | 3.14% | $22.85B | Nov 14, 2025 | ▲ 550.8K |
VESTAL POINT CAPITAL, LP pharmaceutical preparations | 2.67M | 2.60% | 2.60% | $18.86B | Nov 14, 2025 | ▼ 325.0K |
PICTET ASSET MANAGEMENT HOLDING SA pharmaceutical preparations | 2.37M | 2.30% | 2.30% | $16.73B | Nov 18, 2025 | ▼ 1.35M |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
24
Increased
+5.87M shares4
New Positions
first time holders16
Decreased
−6.58M shares0
Sold Out
fully exitedNet shares change (top 50)
714.3K
+5.87M / −6.58M
Net new holders
+12
4 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
DAWN insider trading · insider activity
Source: SEC Form 4
0
Buy transactions
44
Sell transactions
0.00
Buy/Sell ratio
$4M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
AI Day1 LLC 10 percent owner | Apr 23, 2026 | U-Tender | 12,929,322 | $21.50 | $277.98M | 0 | Form 4 ↗ |
AI Day1 LLC 10 percent owner | Apr 23, 2026 | D-Return | 827,586 | $0.00 | $82.759 | 0 | Form 4 ↗ |
Bender Jeremy CHIEF EXECUTIVE OFFICER | Apr 23, 2026 | D-Return | 808,285 | $0.00 | $80.829 | 0 | Form 4 ↗ |
Bender Jeremy CHIEF EXECUTIVE OFFICER | Apr 23, 2026 | D-Return | 286,000 | $8.99 | $2.57M | 0 | Form 4 ↗ |
Bender Jeremy CHIEF EXECUTIVE OFFICER | Apr 23, 2026 | D-Return | 355,000 | $11.16 | $3.96M | 0 | Form 4 ↗ |
Bender Jeremy CHIEF EXECUTIVE OFFICER | Apr 23, 2026 | D-Return | 222,188 | — | — | 0 | Form 4 ↗ |
VASCONCELLES MICHAEL Head of Research and Dev. | Apr 23, 2026 | D-Return | 4,397 | $0.00 | $0.44 | 0 | Form 4 ↗ |
VASCONCELLES MICHAEL Head of Research and Dev. | Apr 23, 2026 | D-Return | 346,000 | $6.64 | $2.30M | 0 | Form 4 ↗ |
VASCONCELLES MICHAEL Head of Research and Dev. | Apr 23, 2026 | D-Return | 171,000 | $11.16 | $1.91M | 0 | Form 4 ↗ |
VASCONCELLES MICHAEL Head of Research and Dev. | Apr 23, 2026 | D-Return | 106,875 | — | — | 0 | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Day One Biopharmaceuticals, Inc. (DAWN) is primarily owned by institutional investors, who hold approximately 82.9% of total shares outstanding. Company insiders own approximately 30.95%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Day One Biopharmaceuticals, Inc. is FMR LLC, holding approximately 10.10 million shares — equal to 9.80% of outstanding shares — as of September 30, 2025.
A total of 176 institutional investors currently hold DAWN stock, with a combined institutional value of approximately $603,966,780 as of the most recent 13F filing period.
Frequently asked questions
DAWN ownershipDay One Biopharmaceuticals, Inc. (DAWN) is primarily owned by institutional investors, who hold approximately 82.9% of shares. The largest shareholder is FMR LLC with a 9.80% stake. Company insiders hold 30.95%. Data sourced from SEC Form 13F as of September 30, 2025.